[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Ahn SH, Han KH, Park JY, Youn YH, Moon CM, Lee KS, Chon CY, Moon YM, Lee DY, Lee JT: Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). Yonsei Med J; 2004 Oct 31;45(5):847-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa).
  • Transcatheter arterial chemoinfusion (TACI) is the main treatment modality for advanced hepatocellular carcinoma (HCC).
  • However, the therapeutic efficacy of TACI according to anti-cancer agents and prognostic factors for advanced HCC (TNM stage IVa) has not been previously clarified.
  • A total of 127 patients with TNM stage IVa HCC were divided into intra-arterial Adriamycin (Group I) and intra-arterial Cisplatin (Group II) infused groups, according to the anticancer agents that were used.
  • We compared the therapeutic efficacy of TACI applied anticancer agents, and we also analyzed the prognostic factors which influenced the survival rates.
  • On univariate analysis, the significant prognostic factors included age, portal vein thrombosis (PVT), tumor size (diameter > 5 cm), type of tumor, the reduction rate (tumor size and alpha- fetoprotein) after 3 months of chemotherapy, serum albumin level, serum alkaline phosphatase level and total serum bilirubin levels at the time of diagnosis.
  • After repeated chemotherapy, Group I showed better survival (14.0 vs 7.9 months).
  • However, there was no statistical difference in the survival rate of the two groups for cases involving large tumors, PVT and diffuse type of HCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15515195.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


2. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R, Mühlbacher F: Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant; 2005 Apr;5(4 Pt 1):788-94
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?
  • The aim of this prospective randomized study was to determine whether additional doxorubicin chemotherapy improves outcome in patients with hepatocellular carcinoma (HCCA) treated by liver transplantation.
  • Stratification parameters were tumor stage (UICC I-IVa), gender, age 50 years, alpha-fetoprotein 20 ng/mL, cirrhosis and HbsAg status.
  • For pre-operative chemotherapy doxorubicin (15 mg/m2) was given biweekly, intra-operative chemotherapy was a single dose administered before surgical manipulation.
  • Post-operative chemotherapy from day 10 was as given preoperatively for a total dosage of 300 mg/m2.
  • Of the 75 consecutive patients who received liver transplantation for treatment of HCCA, 62 patients were enrolled.
  • Thirty-four patients were randomized in the chemotherapy group; 28 patients were in the control group and transplanted only.
  • OS rates at 5 years were 38% in the chemotherapy group and 40% in the control group, disease-free survival rates at 5 years 43% and 53%, respectively.
  • Tumor stage and vascular invasion were identified as independent risk factors for recurrence of disease.
  • Doxorubicin chemotherapy did not improve organ survival and disease-free survival in patients undergoing liver transplantation for HCCA.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacology. Liver Transplantation
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Risk Factors. Survival. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15760403.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


3. Park KW, Park JW, Cho SH, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Kim DY, Hong EK, Kim CM: [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. Korean J Hepatol; 2006 Mar;12(1):41-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities].
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor.
  • For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea.
  • METHODS: Between November 2000 and December 2003, 905 patients with HCC who were diagnosed and treated at the National Cancer Center Korea were enrolled in this study.
  • The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively.
  • The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR.
  • The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081).
  • As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV.
  • The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC.
  • CONCLUSIONS: This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565605.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T: Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol; 2007 Nov 7;13(41):5465-70
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.
  • AIM: To investigate the poor prognosis of HCC with PVTT, we evaluated the efficacy by a new combination chemotherapy for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
  • METHODS: From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil.
  • RESULTS: The mean course of chemotherapy was 14.4 (range, 9-21) mo.
  • One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%).
  • The median survival time after the therapy was 457.2 d.
  • CONCLUSION: Although the prognosis of most patients with Stage IVA HCC by PVTT is poor, our combination chemotherapy may induces long-term survival and is an effective treatment and produced anti-tumor activity with tolerable adverse effects in patients for advanced Stage IVA HCC accompanied by PVTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / drug therapy. Portal Vein. Venous Thrombosis / etiology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Carboplatin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Severity of Illness Index. Tablets, Enteric-Coated. Tegafur / administration & dosage. Time Factors. Treatment Outcome. Uracil / administration & dosage


5. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M: Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res; 2003 Sep 1;9(10 Pt 1):3679-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma.
  • PURPOSE: Retinoid analogues have been reported to inhibit the growth of hepatocellular carcinoma (HCC).
  • In this study, we investigated the expression of RAR mRNAs and proteins in resected HCC and nontumor liver tissue.
  • EXPERIMENTAL DESIGN: Reverse transcription-PCR and Western blot analysis were applied to investigate the expression of RAR mRNAs and proteins in 32 resected samples of HCC and 14 samples of nontumor liver tissue.
  • RESULTS: The intensities of mRNA and protein for RAR-alpha in HCC tissue were significantly higher than those in nontumor liver tissue (P = 0.002 and P = 0.002, respectively).
  • The intensity ratios of HCC versus nontumor liver for RAR-alpha mRNA and protein were significantly higher than those for RAR-beta and RAR-gamma (mRNA, P = 0.02 and P = 0.006; protein, P = 0.04 and P = 0.007, respectively).
  • There was only one significant correlation between the higher intensity of RAR-beta protein and tumor stage (stage I/II versus stage III/IVA, P = 0.01) among clinicopathological variables in the HCC patients.
  • However, in vitro experiments showed that the growth of a RAR-alpha-elevated HCC cell line was potently inhibited by treatment with retinoids at concentrations that did not affect the growth of primary-cultured hepatocytes.
  • CONCLUSIONS: These results imply that RAR-alpha is the dominant receptor in HCC, which suggests that RAR-alpha-selective retinoid analogues may be useful for chemotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Receptors, Retinoic Acid / biosynthesis
  • [MeSH-minor] Blotting, Western. Cell Division. Cell Line, Tumor. Cell Nucleus / metabolism. Dose-Response Relationship, Drug. Humans. Liver / metabolism. Neoplasms / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506158.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 0 / retinoic acid receptor gamma
  •  go-up   go-down


6. Nakagawa Y, Todoroki T, Kondo T, Kawamoto T, Ohkohchi N, Ohara K: A salvage treatment for solid liver metastasis after radical resection of Klatskin tumour. HPB (Oxford); 2003;5(4):254-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A salvage treatment for solid liver metastasis after radical resection of Klatskin tumour.
  • BACKGROUND: Long-term survival has not been described following surgical resection for liver metastasis after radical resection of an advanced hilar bile duct carcinoma (Klatskin tumour).
  • One such patient who developed liver metastasis after radical treatment for stage IVA (pTNM) hilar cholangiocarcinoma has survived 5.5 years after resection of the liver metastasis followed by chemotherapy.
  • CASE REPORT: A 50-year-old man developed a solid liver metastasis in segment VIII 17 months after radical resection of a stage IVA (pT3 pN I MO) Klatskin tumour followed by postoperative radiotherapy (54 Gy) and systemic chemotherapy (oral UFT 450 mg/day plus intravenous cisplatin 20 mg on 5 consecutive days each month).
  • The patient is alive at 7 years after the primary resection followed by resection of the liver metastasis plus further systemic chemotherapy comprising oral UFT combined with intravenous adriamycin (ADM) and mitomycin C (MMC).
  • CONCLUSION: Aggressive salvage resection surgery can be an effective component of a multidisciplinary treatment regimen, even for a postoperative liver metastasis that developed after radical resection of an advanced Klatskin tumour, provided that the metastasis is solid and has not failed local-regional control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):581-7 [10701737.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):364-70 [11260100.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):644-9 [10919004.001]
  • [Cites] Br J Surg. 2000 Mar;87(3):306-13 [10718799.001]
  • (PMID = 18332997.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020601
  •  go-up   go-down


7. Chirica M, Scatton O, Massault PP, Aloia T, Randone B, Dousset B, Legmann P, Soubrane O: Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery? Arch Surg; 2008 Jun;143(6):538-43; discussion 543
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery?
  • HYPOTHESIS: A subset of patients with stage IVA hepatocellular carcinoma (HCC) and preserved liver function may benefit from hepatic resection.
  • PATIENTS: Twenty patients who underwent surgical treatment for stage IVA HCC between July 1998 and October 2004 were identified from the database.
  • With a median follow-up of 23 months, 14 patients (70%) developed recurrence.
  • Treatment of recurrence was possible in 10 patients and included transarterial chemoembolization in 7 patients (35%), of whom 2 (10%) had radiofrequency ablation first, and systemic chemotherapy in 3 patients (15%).
  • Median survival time was 32 months, and the actuarial 1-, 3-, and 5-year survival rates were 73%, 56%, and 45%, respectively.
  • Patients with stage IVA HCC should be followed up by a multidisciplinary team because recurrence is common and sequential treatments may prolong survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Biopsy. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2008 Dec;143(12):1235-6; author reply 1236 [19075180.001]
  • (PMID = 18559745.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM: Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol; 2009 Feb;63(3):459-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
  • PURPOSE: The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC).
  • METHODS: We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007.
  • RESULTS: One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb.
  • Tumor response and disease stability were significantly higher in patients with serum alpha-FP < 400 ng/mL, those with CLIP score < or = 2, and those with a uninodular intrahepatic tumor or no residual intrahepatic tumor with extrahepatic tumors alone (P < 0.05).
  • The median time to progression (TTP) and median overall survival were 2.8 months (95% CI 2.5-3.1 months) and 10.5 months (95% CI 7.9-13.1 months), respectively.
  • CONCLUSIONS: Although XP chemotherapy produced moderate survival outcomes in advanced HCC patients, it was efficacious in the treatment of HCC patients with a uninodular or no residual intrahepatic tumor, especially women, regardless of extrahepatic tumor status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437384.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. De la Revilla NJ, Moreno JM, Rubio E, de Herreros TA, Navarrete E, Lopez MJ, Turrion VS, Jimenez M, Lucena M, Cuervas-Mons V: Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transplant Proc; 2003 Aug;35(5):1830-1
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas.
  • INTRODUCTION: The effectiveness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in patients with advanced hepatocellular carcinoma is controversial.
  • AIM: Our goal was to assess the outcomes of patients with advanced hepatocellular carcinoma treated with chemotherapy after liver transplant.
  • METHODS: Ten patients with liver transplants performed between 1993-2002 were men of mean age 55 years.
  • Immunosuppressive therapy was cyclosporine in five patients and tacrolimus in five.
  • The chemotherapy regimen used adriamycin (20 mg/m2 weekly for 20 weeks).
  • Six patients were stage IVA and four stage III.
  • Hepatocellular carcinoma was known in five patients and incidental in the other five.
  • Pathology revealed well-differentiated hepatocellular carcinoma in six patients and moderately differentiated hepatocellular carcinoma in four.
  • Disease-free survival among patients with stage III was 50% and 80% for stage IVA.
  • Disease-free survival rates were 83% in patients with well-differentiated hepatocellular carcinoma and 25% in those with moderately differentiated hepatocellular carcinoma.
  • Tolerance of chemotherapy was good with two withdrawals due to nephrotoxicity and myelotoxicity and one death from pneumonia.
  • CONCLUSION: The use of adriamycin in patients undergoing liver transplant due to advanced hepatocellular carcinoma may be useful to prevent tumor recurrence; it is well tolerated.
  • The presence of vascular tumor invasion and a lower grade of histologic differentiation were associated with a poor prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / surgery. Doxorubicin / therapeutic use. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Retrospective Studies


10. Sato I, Ueda N, Kinoshita E, Minato H, Ohno K, Nakaya N, Shimasaki T, Nakajima H, Kosaka T, Motoo Y: [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1341-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
  • A 73-year-old man diagnosed as having pancreatic body cancer with multiple liver metastases was referred to our hospital.
  • The liver metastases disappeared and the pancreatic tumor was markedly reduced in size at the completion of 4 courses.
  • Distal pancreatectomy was carried out at 7 months since his first visit.
  • Pathological diagnosis was non-functioning well-differentiated neuroendocrine carcinoma (pT4, pN0, pM0, Stage IVa).
  • S-1 might be a candidate for chemotherapy for this neuroendocrine tumor.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Liver Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Neuroendocrine Tumors / pathology. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Liu CL, Fan ST, Lo CM, Ng IO, Poon RT, Wong J: Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg; 2003 Jan;138(1):100-4
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for bilobar hepatocellular carcinoma: is it justified?
  • HYPOTHESIS: Patients with bilobar stage IVa hepatocellular carcinoma (HCC) are generally considered unsuitable for hepatic resection.
  • Recent data suggest that palliative hepatic resection in selected patients with advanced HCC may result in a favorable survival outcome.
  • The aim of the present study was to evaluate the operative outcome and survival benefits of hepatic resection for patients with bilobar HCC.
  • PATIENTS: The study comprised 78 patients who were diagnosed as having unilobar HCC and considered initially suitable candidates for curative hepatic resection on preoperative investigations from 1989 to 2000.
  • Fifteen patients (19%) underwent palliative hepatic resection (group A), and hepatic resection was not performed in the remaining 63 patients (81%) (group B).
  • In group A, 12 patients (80%) underwent major hepatic resection, and the mean +/- SEM size of the resected tumors was 8.3 +/- 0.9 cm.
  • Treatment for tumors in the contralateral lobe included wedge excision (5 patients), alcohol injection (5 patients), cryotherapy (2 patients), and transarterial oily chemoembolization (3 patients).
  • In group B, treatment for HCC included transarterial oily chemoembolization (42 patients), systemic chemotherapy (3 patients), transarterial oily chemoembolization and systemic chemotherapy (5 patients), cryotherapy (2 patients), tamoxifen (3 patients), and no treatment (8 patients).
  • On multivariate analysis, hepatic resection and preoperative serum alpha-fetoprotein level were the 2 independent factors that significantly affected patient survival.
  • CONCLUSIONS: Hepatic resection for HCC in patients with stage IVa bilobar disease results in a better survival outcome than nonresectional therapies.
  • It should be considered in selected patients with low operative risks and satisfactory liver function.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Palliative Care / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Laparoscopy. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12511161.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Tatekawa Y, Asonuma K, Uemoto S, Inomata Y, Tanaka K: Liver transplantation for biliary atresia associated with malignant hepatic tumors. J Pediatr Surg; 2001 Mar;36(3):436-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for biliary atresia associated with malignant hepatic tumors.
  • The authors report 3 cases of liver transplantations in children between 4 and 10 years of age, complicated with malignant hepatic tumors after biliary atresia.
  • The preoperative abdominal computed tomography (CT) scans of all 3 cases showed hepatic masses.
  • After living-related liver transplantation (LRLT), the pathologic findings of the masses in the resected livers showed hepatocellular carcinoma in 2 cases and hepatoblastoma in the other.
  • The stage of the liver tumor in the 3 cases using the TNM system was IVA (T4, N0, M0), II (T2, N0, M0) and IVA (T4, N0, M0).
  • Chemotherapy was used in all cases after liver transplantation, and all patients survived with no recurrence.
  • The results suggest that even though malignant liver tumors rarely are complicated with biliary atresia in childhood, one should be alert to the occurrence of hepatic malignancy and perform routine screening of alpha-fetoprotein levels, abdominal CT scans, and magnetic resonance imagings.
  • [MeSH-major] Biliary Atresia / complications. Carcinoma, Hepatocellular / complications. Hepatoblastoma / complications. Liver Neoplasms / complications. Liver Transplantation. Postoperative Complications
  • [MeSH-minor] Biomarkers, Tumor / blood. Child. Child, Preschool. Female. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / etiology. Male. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Biliary Atresia.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11226990.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  • [Number-of-references] 25
  •  go-up   go-down


13. Suzuki S, Goto M, Okamoto T, Tomita I, Murayama A, Sawa M, Noguchi Y, Hoshikawa Y, Shimizu A: [A case of small cell carcinoma of the esophagus with SIADH]. Gan To Kagaku Ryoho; 2010 Jan;37(1):123-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell carcinoma of the esophagus with SIADH].
  • Endoscopic biopsy revealed small cell carcinoma.
  • Under diagnosis of small cell carcinoma of the esophagus at Stage IVa, neoadjuvant chemotherapy with FP (5-FU+CDDP) was given.
  • Immediately after fluid load, levels of serum sodium decreased to 117 mEq/L and persisted during chemotherapy treatment despite aggressive corrections.
  • Lymph node and liver metastases recurred.
  • [MeSH-major] Carcinoma, Small Cell / complications. Esophageal Neoplasms / complications. Inappropriate ADH Syndrome / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087045.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi T, Saisho H, Kawata T, Ito H: Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1357-62
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
  • PURPOSE: To evaluate local effects and acute toxicities of involved field irradiation with concurrent cisplatin (CDDP) for unresectable pancreatic carcinoma.
  • MATERIALS AND METHODS: Thirty-three patients with unresectable pancreatic carcinoma were treated with chemoradiotherapy.
  • Sixteen were Stage IVA; 17 were Stage IVB.
  • The total prescribed dose of radiotherapy was 50 Gy/25 fractions or 50.4 Gy/28 fractions, using a three-dimensionally determined involved-field that included only the primary tumor and clinically enlarged lymph nodes.
  • Twelve patients received a daily i.v. infusion of CDDP; 21 patients received a combination of CDDP and 5-fluorouracil either i.v. or through the proper hepatic artery.
  • The most frequent site of disease progression was the liver, and only 3 patients developed local progression alone.
  • No regional lymph nodal progression outside the treatment field was seen.
  • Median survival time and survival at 1 year were 7.1 months and 27%, respectively, for the entire group.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Abdominal Pain / drug therapy. Adult. Aged. Back Pain / drug therapy. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029793.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Takano S, Watanabe Y, Ohishi H, Kono S, Nakamura M, Kubota N, Iwai S: Multimodality treatment for patients with hepatocellular carcinoma: a single institution retrospective series. Eur J Surg Oncol; 2000 Feb;26(1):67-72
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for patients with hepatocellular carcinoma: a single institution retrospective series.
  • BACKGROUND: The main therapeutic options for hepatocellular carcinoma (HCC) are hepatic resection, transcatheter arterial embolization (TAE), percutaneous ethanol injection therapy (PEIT) and regional chemotherapy (RC).
  • METHODS: This study retrospectively examined the results of primary treatment of 600 patients with hepatocellular carcinoma selected according to the treatment guidelines of our facility and the results of various combination therapies for recurrent cases.
  • The selection criteria of therapeutic options included the number and size of tumours and hepatic function.
  • RESULTS: The selected primary treatment was hepatic resection for 53.7% of the cases, TAE for 31.5%, PEIT for 8.2% and RC for 6.6%,.
  • The treatment for post-resection recurrence was TAE alone for 62.4% of the cases, TAE + RC for 4.0%, PEIT for 15.2%, TAE + PEIT alone for 4.8%, RC for 8.0% and hepatic resection for 5.6%.
  • The treatment for post-TAE recurrence was TAE alone for 83% of the cases, TAE + PEIT for 9%, TAE + RC for 3%, RC alone for 3% and PEIT alone for 2%.
  • For post-PEIT, therapy was PEIT alone for 71.4% of the cases and PEIT + TAE for 28.6%.
  • The cumulative 3 and 5-year survival rates were 84.4% and 70.6%, respectively for stage I; 61.5% and 48.6% for stage II; 52.7% and 20.5% for stage III; and 22.8% and 17.1% for stage IVA.
  • The cumulative 5 and 7-year survival rates after the primary treatments were 52.
  • % and 40.1%, respectively, for hepatic resection; 46.5% and 38.7%, for TAE; 49.6% and 33.1% for PEIT; and 16.7% and 8.3% for RC.
  • CONCLUSIONS: To improve the treatment results for HCC, early detection is essential and various modalities of treatments in combination should be used for recurrence after primary treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic. Ethanol / administration & dosage. Hepatectomy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718183.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


16. Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM: [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol; 2007 Dec;13(4):530-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea].
  • BACKGROUND AND AIMS: We investigated the five-year survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients who were treated at a single institute, and this is a follow-up study of a previous report.
  • METHODS: Nine hundred four HCC patients who were treated at the National Cancer Center Korea were enrolled and they were followed till February 2007.
  • The 5-YSRs of the patients with modified UICC stage I, II and III were 61.2%, 54.4% and 18.4%, respectively, and the median survival time was 4.3 and 3.7 months for the stage IVa and IVb patients, respectively.
  • For the analysis of the treatment modality, surgical resection showed significantly better outcomes for the five-year survival as compared with transcatheter arterial chemoembolization (TACE) for Child-Pugh A patients with modified UICC stage I or II disease (80.1% vs 52.8%, respectively, P<.001), or stage III disease (60.7% vs 17.0%, respectively, P<.001).
  • For patients with advanced stage IVb disease, TACE, systemic chemotherapy and radiotherapy increased the median survival period more than conservative management for the Child-Pugh class A patients.
  • The serum alpha-fetoprotein level, portal vein tumor thrombosis, the Child-Pugh class, the tumor stage, the tumor type and symptoms were related to the prognosis.
  • CONCLUSIONS: This study presented, for the first time, the 5-YSRs of a cohort of HCC patients.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Aged. Chemoembolization, Therapeutic. Cohort Studies. Combined Modality Therapy. Female. Humans. Korea. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy, Conformal. Severity of Illness Index. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159151.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


17. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol; 2008 Mar;23(3):467-73
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
  • BACKGROUND AND AIM: To investigate the clinical characteristics and survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients treated at a single institute in a hepatitis B virus (HBV)-endemic area.
  • The 4-year survival rates for Child-Pugh class A patients treated by resection or transarterial chemoembolization (TACE) were 77.3% and 63.2% for those with modified International Union Against Cancer (UICC) stage I or II disease (P = 0.043), and 58.6% and 19.2% for those with modified UICC stage III disease (P < 0.001).
  • In patients with Child-Pugh class A and stage IVa, the median survival times differed between TACE and chemotherapy treatments (6.9 vs 4.0 months, P = 0.003), whereas in patients with stage IVb there was no difference between treatments (8.5 vs 6.1 months, P = 0.173) Serum alpha-fetoprotein level, presence of portal vein tumor thrombosis, Child-Pugh class, tumor, node, and metastasis stage, and the number and type of HCC were all related to prognosis.
  • CONCLUSIONS: The results of this study will be helpful in determining the survival outcomes and treatment strategies for HCC patients in HBV-endemic areas.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Endemic Diseases. Hepatitis B / epidemiology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Catheter Ablation. Chemoembolization, Therapeutic. Female. Follow-Up Studies. Hepatectomy. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Patient Selection. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Severity of Illness Index. Time Factors. Treatment Outcome. Venous Thrombosis / etiology. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764529.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg; 2007 Jun;245(6):831-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
  • OBJECTIVE: We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be improved.
  • SUMMARY BACKGROUND DATA: Recurrence is common after hepatic resection for HCC.
  • Interferon possesses antiviral, immunomodulatory, antiproliferative, and antiangiogenic effects and may be an effective form of adjuvant therapy.
  • PATIENTS AND METHODS: Since February 1999, patients with no residual disease after hepatic resection for HCC were randomly assigned with stratification by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m (IFN-I group) or 30 MIU/m (IFN-II group) thrice weekly for 16 weeks.
  • Enrollment to the IFN-II group was terminated from January 2000 because adverse effects resulted in treatment discontinuation in the first 6 patients.
  • After adjusting for the confounding prognostic factors in a Cox model, the relative risk of death for interferon treatment was 0.42 (95% CI, 0.17-1.05; P = 0.063).
  • Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM stage I/II tumor (5-year survival 90% in both groups; P = 0.917) but prevented early recurrence and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68% (P = 0.038).
  • CONCLUSION: In a group of patients with predominantly hepatitis B-related HCC, adjuvant interferon therapy showed a trend for survival benefit, primarily in those with pTNM stage III/IVA tumors.
  • Further larger randomized trials stratified for stage are needed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chi-Square Distribution. Combined Modality Therapy. Female. Hepatectomy. Hepatitis B / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Recombinant Proteins. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-18-S6-25 [9151912.001]
  • [Cites] Hepatology. 1997 Feb;25(2):259-62 [9021931.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):808-14 [9485039.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):827-35 [9486570.001]
  • [Cites] Hepatology. 1999 Mar;29(3):971-5 [10051505.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] Lancet. 1999 Mar 6;353(9155):797-801 [10459961.001]
  • [Cites] Arch Surg. 1998 Feb;133(2):183-8 [9484732.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1094-101 [10694562.001]
  • [Cites] Hepatology. 2000 Jul;32(1):43-8 [10869287.001]
  • [Cites] Hepatology. 2000 Aug;32(2):228-32 [10915728.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):802-7 [11022927.001]
  • [Cites] Ann Intern Med. 2001 May 15;134(10):963-7 [11352697.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2378-85 [11413528.001]
  • [Cites] Drugs. 2001;61(15):2263-88 [11772139.001]
  • [Cites] Lancet Oncol. 2002 Oct;3(10):593-603 [12372721.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):437-48 [12644537.001]
  • [Cites] J Viral Hepat. 2003 Jul;10(4):298-305 [12823597.001]
  • [Cites] J Gastrointest Surg. 2003 Jul-Aug;7(5):587-94 [12850669.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):376-82 [14716774.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):970-7 [6088019.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5767-71 [3019535.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):527-9 [2535996.001]
  • [Cites] Br J Cancer. 1989 Dec;60(6):928-33 [2557881.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):2091-7 [1587429.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S137-42 [1333900.001]
  • [Cites] Hepatology. 1993 Mar;17(3):389-94 [8383088.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):488-94 [8392955.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1471-6 [8224650.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):543-50 [7539237.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1422-7 [8618580.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • [CommentIn] Ann Surg. 2007 Jun;245(6):843-5 [17522507.001]
  • (PMID = 17522506.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1876947
  •  go-up   go-down


19. Shim JH, Park JW, Choi JI, Park BJ, Kim CM: Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol; 2009 Apr;135(4):617-25
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
  • BACKGROUND: This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection.
  • METHODS: Medical records of 57 consecutive patients with unresectable or metastatic HCC treated with 400 mg bid sorafenib at the National Cancer Center, Korea between June 2007 and March 2008, were retrospectively reviewed.
  • Eleven patients (19.3%) had modified UICC stage III tumors, 11 (19.3%) had stage IVa, and 35 (61.4%) had stage IVb.
  • Following sorafenib monotherapy, 3 patients (5.3%) achieved a partial response and 18 (35.1%) achieved stable disease, with a disease control rate of 40.4%.
  • The median times to progression (TTP) was 9.1 weeks (95% CI 3.4-14.8 weeks).
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis B / epidemiology. Liver Neoplasms / drug therapy. Pyridines / therapeutic use. Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Hepatitis C / epidemiology. Humans. Korea. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2009 Feb;63(3):459-67 [18437384.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2606-10 [11420671.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Dec;133(12):937-43 [17516087.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):755-62 [17951335.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):117-23 [18221915.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1331-5 [10889387.001]
  • [Cites] Korean J Hepatol. 2004 Jun;10(2):88-98 [15218342.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):467-73 [17764529.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Apr 1;17(7):1843-9 [17289388.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):250-9 [18041064.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Hepatol Res. 2002 Dec;24(4):395-403 [12479938.001]
  • (PMID = 18846384.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


20. Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, Li KQ, Jin CB, Xie FL, Su HB: Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology; 2005 May;235(2):659-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization.
  • PURPOSE: To evaluate ultrasonographically (US)-guided high-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization (TACE) in the treatment of stage IVA hepatocellular carcinoma (HCC).
  • From November 1998 to May 2000, 50 consecutive patients with stage IVA HCC (TNM classification, T4N0-1M0) were alternately enrolled in one of two treatment groups: group 1 (n = 26), in which TACE was performed alone, and group 2 (n = 24), in which transcutaneous ablation of HCC with high-intensity focused ultrasound was performed 2-4 weeks after TACE.
  • Immediate therapeutic effects were assessed at follow-up with Doppler US and computed tomography or magnetic resonance imaging.
  • All patients were followed up for 3-24 months (mean, 8 months) to observe long-term therapeutic effects and complications in both groups.
  • Tumor reduction rates, median survival time, and cumulative survival rates in both groups were calculated by using the unpaired Student t test and Kaplan-Meier method.
  • The median survival time was 11.3 months in group 2 and 4.0 months in group 1 (P = .004).
  • Median reductions in tumor size as a percentage of initial tumor volume at 1, 3, 6, and 12 months after treatment, respectively, were 28.6%, 35.0%, 50.0%, and 50.0% in group 2 and 4.8%, 7.7%, 10.0%, and 0% in group 1 (P < .01).
  • CONCLUSION: The combination of high-intensity focused ultrasound ablation and TACE is a promising approach in patients with advanced-stage HCC, but large-scale randomized clinical trials are necessary for confirmation.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Ultrasonic Therapy / methods
  • [MeSH-minor] Adult. Aged. Calibration. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Transducers. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • [CommentIn] Radiology. 2005 May;235(2):345-6 [15858077.001]
  • (PMID = 15858105.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Punushapai U, Yuenyao P, Chumworathayi B, Luanratanakorn S, Udomthavornsuk B: Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial. Asian Pac J Cancer Prev; 2010;11(1):201-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial.
  • OBJECTIVES: To evaluate treatment response and acute treatment-related toxicity of concurrent chemoradiotherapy with cisplatin 20 mg/m2 , compared to 40 mg/m2 as the standard, in locally advanced cervical cancer.
  • SUBJECTS: 140 patients, >60 years old with biopsy-proven previously untreated invasive carcinoma of cervix, FIGO stage IB2-IVA, undergoing concurrent chemoradiotherapy with adequate bone marrow, renal and liver functions, between April and December 2009.
  • Main outcome measures included clinical response, cytological response, and acute treatment-related toxicity.
  • 80% had squamous cell carcinomas; about half were FIGO stage IIIB.
  • The 40 mg/m2 group showed unplanned interruptions in 13/70 (18.6%), which was significantly different from the 5/70 (7.1%) in the 20 mg/m2 group (p=0.02), resulting in prolonged treatment time (p=0.026).
  • No treatment related deaths were encountered.
  • CONCLUSION: This prospective trial has sufficient data to support the conclusion that concurrent chemoradiotherapy with weekly cisplatin 40 mg/m2 in locally advanced cervical cancer gives good treatment outcomes.
  • When reducing the cisplatin dose to 20 mg/m2, treatment responses were still comparable to the standard, but acute toxicity could be reduced.
  • However, there are insufficient data to assess long term treatment outcomes and late treatment related toxicity, because of the short follow-up time.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome


22. Sunamura M, Kobari M, Shibuya K, Takeda K, Matsuno S: [The role of preoperative staging for pancreatic cancer]. Nihon Geka Gakkai Zasshi; 2000 Feb;101(2):212-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative staging for pancreatic cancer].
  • Despite the poor prognosis of pancreatic carcinoma patients, surgical resection remains the only potentially curative treatment.
  • According to the report of a national survey of pancreatic cancer in 1997, patients with S0 or S1, RP0 or RP1, and N0 or N1 disease have longer survival periods compared with patients with S2, RP2, and N2 disease.
  • Therefore patients classified as Stage I, Stage II, or Stage III are recognized as candidates for surgical resection.
  • Patients classified as Stage IVb because of positive P factor or positive H factor are selected for conservative treatment such as chemotherapy and irradiation.
  • It remains to be clarified whether patients classified as Stage IVa should undergo surgical resection or not.
  • Future prospective randomized studies of patients with Stage IVa disease will reveal whether surgical resection or chemoradiation is effective.
  • Helical CT is useful to evaluate S and RP factors for definitive preoperative staging.
  • CT-AP can reveal occult metastases to the liver.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10734639.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


23. Rosenthal DI, Yom SS, Liu L, Machtay M, Algazy K, Weber RS, Weinstein GS, Chalian AA, Mille LK, Rockwell K Jr, Tonda M, Schnipper E, Hershock D: A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs; 2002 Aug;20(3):343-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.
  • BACKGROUND: Liposomal cisplatin preparations have two potential advantages over the free drug when combined with radiation therapy (RT):.
  • 1) selective tumor localization, improving the therapeutic ratio, and 2) prolonged half-life, allowing more radiosensitization.
  • We performed a Phase I study of Stealth liposomal cisplatin (SPI-077) concurrent with RT for head and neck squamous cell carcinoma (HNSCC).
  • METHODS: Patients with Stage IVa/b HNSCC were treated with SPI-077, given intravenously twice two weeks apart, concurrent with RT (60-72 Gy in 6-7 weeks).
  • Two of these patients received one dose because of reversible Grade 3 liver toxicity or rash.
  • Ten of 17 patients (59%) finishing treatment achieved initial complete response.
  • Infusion reactions were minimized with a slower and more dilute initial infusion.
  • The potentially beneficial therapeutic ratio suggests that liposomal radiosensitizer preparations warrant further investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Humans. Infusions, Intravenous / adverse effects. Karnofsky Performance Status. Liposomes. Male. Middle Aged. Neutropenia / chemically induced. Prospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] Int J Radiat Biol. 1990 Jan;57(1):55-64 [1967294.001]
  • [Cites] Oncology (Williston Park). 2000 Dec;14 (12 Suppl 11):52-8 [11204665.001]
  • [Cites] Toxicol Sci. 1998 Nov;46(1):155-65 [9928679.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7 [8703389.001]
  • [Cites] Drugs. 1993 Sep;46(3):360-377 [7693428.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1475-80 [11115157.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):325-38 [11005567.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):693-700 [10442192.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4939-49 [11156255.001]
  • [Cites] Cancer Invest. 2001;19(2):127-36 [11296617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(3):613-7 [1346533.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):425-35 [11197208.001]
  • [Cites] Curr Oncol Rep. 2001 Mar;3(2):156-62 [11177748.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1029-35 [11308249.001]
  • [Cites] Drugs. 2000 Oct;60(4):895-924 [11085200.001]
  • [Cites] Biochim Biophys Acta. 1991 Oct 14;1069(1):117-21 [1932044.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1029-33 [11038041.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):409-22 [10458260.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5135-43 [1394121.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1193-203 [8780628.001]
  • [Cites] Drugs. 1997;54 Suppl 4:30-5 [9361959.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3512-21 [10550149.001]
  • [Cites] Cancer Treat Rep. 1987 Jul-Aug;71(7-8):723-6 [3300967.001]
  • (PMID = 12201498.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / SPI-77, liposomal; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement